EANS Advanced Course in Spinal Surgery

EANS Advanced Course in Spinal Surgery

October 29 — October 31

Munich, Germany
Part I: Extended indications and advanced operative techniques
Registration will open in May 2017. Click HERE to register your interest via the course website.
Part II,  ‘complications and management’, is planned again for 2018.
PART I:

LECTURE TOPICS: Craniocervical junction / Cervicothoracic junction / Thoracic spine / Adolescent idiopathic scoliosis (AIS) / Lumbar degenerative scoliosis / High-grade lumbar spondylolisthesis / Sacrum / Intramural tumours

CADAVER LAB TEACHING: OC/C1/C2 Instrumentation / Thoracic en bloc vertebrectomies / Lumbar osteotomies / Endoscopic odontoid resection / transoral approaches / Cervicothoracic pedicle screws / Posterolateral corcectomies / Sacral resections and sacropelvic fixation techniques

INVITED FACULTY:

Emre Acaroglu (Turkey)
Massimo Balsano (Italy)
Stephanie Combs (Germany)
Maarten Coppes (NL)
Bart Depreitere (Belgium)
John Duff (Switzerland)
Joerg Franke (Germany)
Cumhur Kilincer (Turkey)
Heiko Koller (Germany)
Jesús Lafuente (Spain)
Jens Lehmberg (Germany)
Bernhard Meyer (Germany)
Wouter Moojen (NL)
Wilco Peul (NL)
Dominique A Rothenfluh (UK)
Yu-Mi Riyang (Germany)
Ehab Shiban (Germany)
Claudius Thomé (Austria)
Carmen Vleggeert-Lankamp (NL)

INSIGHTEC’S EXABLATE NEURO NAMED BEST MEDICAL TECHNOLOGY AT ESTEEMED PRIX GALIEN AWARDS 2017

INSIGHTEC, the leader in MR-guided Focused Ultrasound (MRgFUS), has been awarded Best Medical Technology for Exablate Neuro by The Galien Foundation.  Exablate Neuro is an innovative medical technology that uses focused ultrasound coupled with MR imaging (MRgFUS), to precisely target and treat areas deep within the brain through an intact skull.
The prestigious Prix Galien awards recognize excellence in scientific innovations that improve the state of human health. The Best Medical Technology award confirms INSIGHTEC’s vision of transformative healthcare and the company’s determination to improve the daily lives of patients living with essential tremor.
“It’s a great honor to receive this award, which recognizes our dedication to researching and developing a non-invasive medical treatment,” said INSIGHTEC’s CEO and Chairman of the Board, Maurice R. Ferré MD. “Our pursuit of innovation is not only driven by our founder Kobi Vortman, but also by the leading neurosurgery centers which have adopted the Exablate Neuro around the world. This is an exciting time for INSIGHTEC and spurs on our commitment to supporting healthcare professionals, deliver treatments which truly improve the lives of people worldwide.”
Having accepted the award at The American Museum of Natural History in New York City, INSIGHTEC’s Vice President of Marketing, Xen Mendelsohn Aderka added “To be seen as an innovator whilst in the presence of so many renowned figures in the pharmaceutical, biomedical and medical technology industry, is a great accolade. We thank the judges for acknowledging the hard work and dedication of our team.”
The U.S. Food and Drug Administration (FDA) approved Exablate Neuro in July 2016 for the non-invasive treatment of patients with essential tremor who had not responded to medication. Essential tremor is the most common movement disorder, affecting more than 5 million people in the United States, and millions more worldwide. Hand tremor is the most common symptom and for these patients, performing everyday tasks can seem nearly impossible and greatly impacts on their quality of life.

× How can I help you?
WhatsApp WhatsApp us
%d bloggers like this: